



SuperGen Announces Resignation of Dr. Craig Rosenfeld To Pursue Start-Up Opportunity

DUBLIN, Calif., Jan. 30 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG -) today announced that Craig Rosenfeld, M.D. has resigned his position of Chief Scientific Officer and will join a start-up company in the biotechnology field. Although Dr. Rosenfeld will transition out of the position over the next two months, he will be retained as a consultant and Scientific Board member to continue to assist with the Dacogen™ (decitabine) injection program and the company's broader interest in hematology products.

"Dr. Rosenfeld has decided to pursue an opportunity with a start-up company from his hometown of Dallas, and while we are saddened to lose a valuable member of our internal team, Craig was a strong contributor to the Dacogen program prior to coming to SuperGen and we anticipate that our future associations will be equally rewarding," said Dr. James Manuso, President and Chief Executive Officer of SuperGen. "In the meantime, we have already started the process of identifying candidates to fill the position of Chief Scientific Officer."

"The Dacogen program has transitioned from patient accrual to data collection," said Dr. Karl Mettinger, M.D., Ph.D., Senior Vice President and Chief Medical Officer of SuperGen. "Now that the submission of Orathecin™ (rubitecan) capsules has been completed, we can focus our attention on the next submission, Dacogen. We will be meeting with the FDA this quarter and expect to be able to release data of our Phase III trial in myelodysplastic syndrome."

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapeutic anticancer products. The company's website can be reached at www.supergen.com.

This press release contains "forward-looking" statements within the meaning of section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. Such forward-looking statements include statements related to our expectations regarding our proposed meeting with the FDA and our proposed release of data. The timing of such proposed meeting and proposed release of data could differ materially from those discussed in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors include, but are not limited to: risks and uncertainties related to scheduling and completing a meeting with the FDA, that no result of FDA interactions prevents analysis of the data and that the company will have the resources to complete such analysis. References made to the discussion of the risk factors are detailed in the company's filing with the Securities and Exchange Commission including the report on Form 10-Q for the quarter ended September 30, 2003. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Tim Enns, Vice President, Investor Relations & Business Development,
SuperGen Inc., 800-353-1075, ext. 111